J&J to begin testing Ebola vaccine in January; expects 250K doses ready by May

• Johnson & Johnson (NYSE:JNJ) will begin testing an Ebola vaccine in humans in January, and plans to have 250K doses of the experimental vaccine ready for use in clinical trials in May.
• The drug will combine a shot from the company's Janssen unit with one developed by Bavarian Nordic (OTCPK:BVNRY).
• J&J will invest about $200M to study and expand production of the vaccine, and aims to produce 1M doses next year.